Schreiber Y S, Herrera A F, Wilson D, Wallengren K, Draper R, Muller J, Dawood H, Doucette S, Cameron D W, Alvarez G G
Ottawa Health Research Institute, University of Ottawa at The Ottawa Hospital, Ottawa, Ontario, Canada.
Int J Tuberc Lung Dis. 2009 Oct;13(10):1274-80.
Rates of multidrug-resistant tuberculosis (MDR-TB) are currently as high as 7.7% in retreatment cases in KwaZulu-Natal, South Africa. MDR-TB prevalence is known to be high in patients categorized as treatment failures. Recent reports have questioned the effectiveness of the World Health Organization (WHO) Category II regimen in retreatment TB cases.
To determine whether treatment category predicts susceptibility patterns and outcomes in a hospitalized population of retreatment TB cases.
Retrospective cohort of 197 pulmonary retreatment cases.
Retreatment cases treated with the standard retreatment regimen had a high in-hospital mortality (19.8%), or poor outcome (26.4%) and a high rate of MDR-TB (16.2%). The 'treatment failure' category predicted resistance, with 57.1% of patients exhibiting any resistance compared to other treatment categories (P = 0.02); 53.8% of patients with any resistance experienced poor outcomes, compared to 16.6% of pan-susceptible cases (P = 0.02). There was a trend towards poor outcome in the treatment failure category (42.9%, P = 0.13).
The retreatment category 'treatment failure' is associated with a high prevalence of resistance in an area of high human immunodeficiency virus (HIV) prevalence. The 'treatment failure' category should be used to identify patients who may benefit from alternative regimens using directed, intensified therapy or second-line agents instead of the current standard retreatment regimen.
在南非夸祖鲁 - 纳塔尔省的复治病例中,耐多药结核病(MDR - TB)的发生率目前高达7.7%。已知在被归类为治疗失败的患者中,MDR - TB患病率很高。最近的报告对世界卫生组织(WHO)的II类治疗方案在复治结核病病例中的有效性提出了质疑。
确定治疗类别是否能预测住院复治结核病患者群体的药敏模式和治疗结果。
对197例肺部复治病例进行回顾性队列研究。
采用标准复治方案治疗的复治病例住院死亡率高(19.8%),或治疗效果差(26.4%),且MDR - TB发生率高(16.2%)。“治疗失败”类别预示着耐药,与其他治疗类别相比,该类别中有57.1%的患者表现出任何耐药情况(P = 0.02);有任何耐药情况的患者中53.8%治疗效果差,而全敏感病例中这一比例为(P = 0.02)。“治疗失败”类别有治疗效果差的趋势(42.9%,P = 0.13)。
在人类免疫缺陷病毒(HIV)高流行地区,复治类别“治疗失败”与高耐药率相关。“治疗失败”类别应用于识别那些可能从采用针对性强化治疗或二线药物的替代方案中获益的患者,而非目前的标准复治方案。